{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:58:39Z","timestamp":1772189919876,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":10891,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1982,10]]},"abstract":"<jats:p>1 To evaluate oral disopyramide phosphate in the prophylaxis of dysrhythmias occurring in acute myocardial infarction (MI) patients (presenting within 12 h of symptoms, age 21\u201070 years), a placebo\u2010 controlled, randomized double\u2010blind, in hospital trial was conducted. After prognostic stratification (anterior and non\u2010anterior MI at each of 4 regional hospitals) patients were randomly assigned to receive oral disopyramide phosphate (loading dose 150, 200, or 300 mg followed 6 h later by 100, 150, or 200 mg every 6 h for patients assessed to weigh less than 55, 55\u201085, or greater than 85 kg, respectively or matching placebo. The primary exclusion criteria were overt heart failure, systolic BP less than 100 mmHg, significant heart block or history of urinary retention. Active drug or placebo was continued for 7 days or until (a) detection of \u2018warning arrhythmias\u2019 requiring i.v. lignocaine intervention (greater than 5 for 7 days or until (a) detection of \u2018warning arrhythmias\u2019 requiring i.v. lignocaine intervention (greater than 5 premature ventricular contractions (PVCs)\/min, R on T PVCs, multifocal PVCs, bigeminal PVCs, ventricular tachycardia or ventricular fibrillation) or (b) onset of exclusion criteria. In addition, plasma drug concentrations were determined and 24 h electrocardiographic tapes were obtained on day 1, and on one of days 4\u20107 but these results are not presented here. 2 Out of 121 patients entering the trial, 101 had confirmatory ECG and enzyme changes. Of these, 9 of 47 patients receiving disopyramide phosphate required lignocaine compared to 20 of 54 receiving placebo (19% v 37%; P = 0.047). Corresponding numbers for patients discontinuing trial medication for other non\u2010fatal complications of MI were 5 and 3, and for those dying, were 3 (2 infarct extensions and 1 massive infarction), and 0, respectively. Respective numbers discontinuing trial medication for possible drug side effects (viz. urinary retention requiring catheterization) were 6 and 1 (P = 0.031). 3 In circumstances where i.v. therapy is deemed impractical, use of oral disopyramide phosphate given prophylactically in patients with acute MI may reduce the incidence of \u2018warning arrhythmias\u2019 by a clinically significant extent.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1982.tb02023.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T17:06:32Z","timestamp":1343322392000},"page":"519-527","source":"Crossref","is-referenced-by-count":12,"title":["A placebo\u2010controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction."],"prefix":"10.1111","volume":"14","author":[{"given":"CR","family":"Kumana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VS","family":"Rambihar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PH","family":"Tanser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JA","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RN","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RA","family":"Wildeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AL","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Gent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"965P","article-title":"Lignocaine pharmacokinetics in man: dose and time studies.","volume":"3","author":"BENDING M.R.","year":"1976","journal-title":"Br. J. clin. Pharmac."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1971121105"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6122.1254"},{"key":"e_1_2_1_5_1","first-page":"182","article-title":"Sudden death and myocardial infarction.","volume":"39","author":"FULTON M.","year":"1969","journal-title":"Circulation"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac50039a032"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90190-3"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/030006058000800502","article-title":"Prophylactic disopyramide: its clinical effects related to plasma concentration in myocardial infarction.","volume":"8","author":"HILLSON R.M.","year":"1980","journal-title":"J. int. med. Res."},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)90148-3"},{"key":"e_1_2_1_10_1","first-page":"85","article-title":"The pharmacokinetics of Norpace.","volume":"26","author":"KARIM A.","year":"1975","journal-title":"Angiology"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197110282851811"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196912042812301"},{"key":"e_1_2_1_13_1","first-page":"000","article-title":"Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.","volume":"14","author":"KUMANA C.R.","year":"1982","journal-title":"Br. J. clin. Pharmac."},{"key":"e_1_2_1_14_1","first-page":"193","article-title":"Anti\u2010dysrhythmic treatment in acute myocardial infarction.","author":"LANCET EDITORIAL","year":"1979","journal-title":"Lancet"},{"key":"e_1_2_1_15_1","first-page":"379","article-title":"Characteristics and predictability of primary ventricular fibrillation.","volume":"1","author":"LIE K.I.","year":"1974","journal-title":"Eur. J. Cardiol."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197412192912504"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92102-9"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197811000-00002"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198003133021106"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.36.3.265"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.61.1.29"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)93134-7"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90385-2"},{"key":"e_1_2_1_24_1","article-title":"Disopyramide and quinidine in maintenance of sinus rhythm after electroconversion.","author":"WOO K.S.","year":"1980","journal-title":"Circulation"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(74)90259-8"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90829-7"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1982.tb02023.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1982.tb02023.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T10:50:21Z","timestamp":1699699821000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1982.tb02023.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1982,10]]}},"alternative-id":["10.1111\/j.1365-2125.1982.tb02023.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1982.tb02023.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,10]]}}}